How to Help Your Patients Find Qulipta in Stock: A Provider's Guide

Helping Patients Find Qulipta: A Provider's Guide

You've prescribed Qulipta (Atogepant) for your patient's migraine prevention — and then the phone calls start. "My pharmacy doesn't have it." "They said it's on backorder." "I've been waiting two weeks."

These conversations are familiar to providers who prescribe CGRP-based therapies. While Qulipta is not in a formal FDA-listed shortage, real-world pharmacy availability gaps create a frustrating experience for patients and unnecessary workload for your practice.

This guide provides actionable steps you and your staff can take to minimize these disruptions and keep patients on their prescribed therapy.

Current Availability Landscape

Qulipta is manufactured by AbbVie and available in 10 mg, 30 mg, and 60 mg oral tablets. The current WAC is $1,204.57 per 30-day supply (January 2026). Key facts about the availability landscape:

• Not on FDA shortage list: No manufacturing or supply chain disruption
• No generic available: Brand-name only (patent challenges eligible since September 2025, but no ANDA approved)
• PA required: Virtually all commercial and Part D plans require prior authorization
• Limited retail stocking: Many chain pharmacies don't routinely carry Qulipta due to cost and volume considerations

Why Patients Can't Find Qulipta

Understanding the barriers helps you address them proactively:

1. Retail Pharmacy Inventory Practices

Chain pharmacies typically stock medications based on dispensing volume. A pharmacy that fills one or two Qulipta prescriptions per month may not keep it in regular inventory. Each bottle represents over $1,200 in inventory cost, which pharmacies may not want to hold without guaranteed demand.

2. Prior Authorization Timing

PA processing typically takes 5-14 business days. Pharmacies generally won't order a specialty drug until PA is confirmed, creating a gap between when you prescribe and when the patient can fill. This is the most common source of patient frustration.

3. Insurance Formulary Restrictions

Some plans place Qulipta on a non-preferred specialty tier or require step therapy through generics (Topiramate, Propranolol) and sometimes through an injectable CGRP before approving an oral gepant.

4. Patient Cost Barriers

Even with insurance, specialty tier copays can be $50-$200+ per month. Without insurance, the cash price exceeds $1,200. Patients may abandon their prescription at the pharmacy counter if the cost is higher than expected.

5. Geographic Disparities

Patients in rural areas or regions with limited pharmacy options face compounded challenges. Fewer pharmacies means fewer potential sources, and specialty pharmacies may not have physical locations nearby.

What Providers Can Do: 5 Actionable Steps

Step 1: Submit PA Proactively at the Point of Prescribing

Don't wait for the pharmacy to trigger the PA. Submit authorization paperwork on the same day you write the prescription. Include:

• Migraine diagnosis with frequency documentation (headache diary if available)
• Previous treatments tried and failed (with dates and reasons for discontinuation)
• MIDAS or HIT-6 scores demonstrating disability
• Clinical rationale for Qulipta specifically (e.g., patient prefers oral over injectable, contraindication to alternatives)

Pre-emptive PA reduces the gap between prescribing and filling by 1-2 weeks.

Step 2: Verify Pharmacy Stock Before Sending the Prescription

Use Medfinder for Providers to check real-time pharmacy availability before sending the prescription. This allows you to route the prescription to a pharmacy that actually has Qulipta in stock, avoiding patient callbacks.

Alternatively, have your staff call the patient's preferred pharmacy to confirm stock or request they order it in advance of the PA approval.

Step 3: Consider Specialty or Mail-Order Pharmacy Routing

Specialty pharmacies and insurance-affiliated mail-order pharmacies are far more reliable sources for Qulipta. Many insurers actually require specialty pharmacy dispensing for CGRP medications. Benefits include:

• Reliable stock levels
• Integrated PA and benefits verification
• Home delivery
• Refill coordination and adherence support

Check the patient's insurance plan for preferred specialty pharmacy networks.

Step 4: Enroll Patients in AbbVie Savings Programs

Before the patient leaves your office, initiate enrollment in cost-reduction programs:

• Qulipta Complete Savings Card: Commercially insured patients may pay $0/month. Up to 2 fills at no cost while PA is pending.
• myAbbVie Assist: For uninsured/underinsured patients with financial need.
• Provider support: 1-855-QULIPTA (1-855-785-4782)

Having the savings card activated before the patient reaches the pharmacy prevents sticker shock and prescription abandonment.

Step 5: Provide Patients with Self-Service Resources

Give patients tools to help themselves if availability issues arise:

• Medfinder — real-time pharmacy stock checker
• AbbVie support: 1-855-785-4782
• Your practice's direct line for PA status inquiries

A printed handout or after-visit summary with these resources can reduce inbound calls to your practice.

Alternative CGRP Options When Qulipta Is Unavailable

If a patient cannot access Qulipta due to insurance, availability, or tolerance, consider these alternatives:

• Nurtec ODT (Rimegepant): Oral gepant, 75 mg every other day. Dual indication for prevention and acute treatment. May have different formulary positioning.
• Aimovig (Erenumab): Monthly SC injection, 70-140 mg. CGRP receptor target. Well-established efficacy data.
• Ajovy (Fremanezumab): Monthly or quarterly SC injection. Offers dosing flexibility.
• Emgality (Galcanezumab): Monthly SC injection. Also indicated for episodic cluster headache.

When switching between CGRP agents, no washout period is typically needed. Consider the patient's preference for oral vs. injectable, dosing frequency, and insurance formulary when selecting an alternative.

For a patient-facing comparison: Alternatives to Qulipta.

Workflow Tips for Your Practice

Implementing these workflow adjustments can reduce Qulipta-related disruptions:

• Create a PA template: Standardize your Qulipta PA submission with pre-populated fields for diagnosis, prior therapies, and clinical justification. This saves staff time and improves approval rates.
• Designate a specialty pharmacy contact: Identify 1-2 reliable specialty pharmacies and establish a direct relationship. Having a go-to contact expedites problem-solving.
• Track PA status: Use your EHR's PA tracking features or a simple spreadsheet to monitor pending authorizations. Follow up at 7 days if no response.
• Batch savings card enrollments: Train front-desk or nursing staff to enroll patients in the Qulipta Complete Savings Card during the visit, not after.
• Bookmark Medfinder for Providers: Add it to your EHR's quick links or bookmark bar for fast pharmacy stock checks.

Final Thoughts

Qulipta access issues are solvable with proactive provider engagement. By submitting PA early, verifying pharmacy stock, routing to specialty pharmacies, and connecting patients with savings programs, you can significantly reduce the friction your patients experience.

The tools exist — Medfinder for Providers, AbbVie's support programs, and specialty pharmacy networks — to keep your migraine patients on effective therapy without unnecessary interruptions.

Related provider resources:

• Qulipta Shortage: What Providers Need to Know
• How to Help Patients Save Money on Qulipta
• Qulipta Drug Interactions: What to Avoid